logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Icosapent ethyl for reducing the risk of cardiovascular events

< Back

Icosapent ethyl for reducing the risk of cardiovascular events

Drugs

Cardiovascular Disease and Vascular Surgery

July 2020


Icosapent ethyl is in clinical development as a treatment to reduce the risk of cardiovascular events in high-risk patients who have their cholesterol levels controlled with statin treatment, but have elevated triglycerides and other cardiovascular risk factors. Cardiovascular events include heart attack, angina and stroke. These diseases are the main cause of death in the UK, accounting for over a quarter of deaths each year. Patients receiving statin treatment are still at a high risk and would benefit from treatment to reduce cardiovascular events.

Icosapent ethyl is an omega-3 fatty acid administered in a capsule. While the way the drug works is not yet known, it is thought to reduce lipid levels and inflammation which play a role in the development of cardiovascular diseases. It has been shown to reduce the risk of major cardiovascular events compared to the placebo in trials and if licenced, would provide an additional preventative therapy for patients on statins.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts